Recombinant Anti-Angiotensinogen antibody [EPR2930(2)] (ab108294)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2930(2)] to Angiotensinogen
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Angiotensinogen antibody [EPR2930(2)]
See all Angiotensinogen primary antibodies -
Description
Rabbit monoclonal [EPR2930(2)] to Angiotensinogen -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: IHC-P -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Fetal kidney, fetal artery, fetal heart, HepG2, and Human plasma lysates
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR2930(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab108294 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/10000 - 1/50000. Predicted molecular weight: 53 kDa.
|
Notes |
---|
WB
1/10000 - 1/50000. Predicted molecular weight: 53 kDa. |
Target
-
Function
Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis. In response to lowered blood pressure, the enzyme renin cleaves angiotensinogen to produce angiotensin-1 (angiotensin 1-10). Angiotensin-1 is a substrate of ACE (angiotensin converting enzyme) that removes a dipeptide to yield the physiologically active peptide angiotensin-2 (angiotensin 1-8). Angiotensin-1 and angiotensin-2 can be further processed to generate angiotensin-3 (angiotensin 2-8), angiotensin-4 (angiotensin 3-8). Angiotensin 1-7 is cleaved from angiotensin-2 by ACE2 or from angiotensin-1 by MME (neprilysin). Angiotensin 1-9 is cleaved from angiotensin-1 by ACE2.
Angiotensin-2 acts directly on vascular smooth muscle as a potent vasoconstrictor, affects cardiac contractility and heart rate through its action on the sympathetic nervous system, and alters renal sodium and water absorption through its ability to stimulate the zona glomerulosa cells of the adrenal cortex to synthesize and secrete aldosterone.
Angiotensin-3 stimulates aldosterone release.
Angiotensin 1-7 is a ligand for the G-protein coupled receptor MAS1 (By similarity). Has vasodilator and antidiuretic effects (By similarity). Has an antithrombotic effect that involves MAS1-mediated release of nitric oxide from platelets. -
Tissue specificity
Expressed by the liver and secreted in plasma. -
Involvement in disease
Genetic variations in AGT are a cause of susceptibility to essential hypertension (EHT) [MIM:145500]. Essential hypertension is a condition in which blood pressure is consistently higher than normal with no identifiable cause.
Defects in AGT are a cause of renal tubular dysgenesis (RTD) [MIM:267430]. RTD is an autosomal recessive severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset oligohydramnios (the Potter phenotype). -
Sequence similarities
Belongs to the serpin family. -
Post-translational
modificationsBeta-decarboxylation of Asp-34 in angiotensin-2, by mononuclear leukocytes produces alanine. The resulting peptide form, angiotensin-A, has the same affinity for the AT1 receptor as angiotensin-2, but a higher affinity for the AT2 receptor. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 183 Human
- Omim: 106150 Human
- SwissProt: P01019 Human
- Unigene: 19383 Human
-
Alternative names
- Aangiotensinogen (serpin peptidase inhibitor clade A member 8) antibody
- AGT antibody
- AI265500 antibody
see all
Images
-
All lanes : Anti-Angiotensinogen antibody [EPR2930(2)] (ab108294) at 1/10000 dilution
Lane 1 : Human fetal kidney lysate
Lane 2 : Human fetal artery lysate
Lane 3 : Human fetal heart lysate
Lane 4 : HepG2 cell lysate
Lane 5 : Human plasma lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 53 kDa
Datasheets and documents
-
SDS download
-
Datasheet download
References (2)
ab108294 has been referenced in 2 publications.
- Gangwar A et al. Intermittent normobaric hypoxia facilitates high altitude acclimatization by curtailing hypoxia-induced inflammation and dyslipidemia. Pflugers Arch N/A:N/A (2019). PubMed: 30980137
- Pandey VG et al. Dexamethasone promotes hypertension by allele-specific regulation of the human angiotensinogen gene. J Biol Chem 290:5749-58 (2015). PubMed: 25568318